Design, Synthesis, Docking Study and Biological Evaluation of 4-Hydroxy-2H-benzo[e][1,2]thiazine-3-carboxamide 1,1-dioxide Derivatives as Anti-HIV Agents

被引:2
作者
Imani, Ali [1 ]
Soleymani, Sepehr [2 ]
Vahabpour, Rouhollah [3 ]
Hajimahdi, Zahra [1 ]
Zarghi, Afshin [1 ]
机构
[1] Shahid Beheshti Univ Med Sci, Sch Pharm, Dept Med Chem, Tehran, Iran
[2] Pasteur Inst Iran, Hepatitis & AIDS Dept, Tehran, Iran
[3] Shahid Beheshti Univ Med Sci, Sch Allied Med Sci, Med Lab Technol Dept, Tehran, Iran
来源
IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH | 2021年 / 20卷 / 03期
关键词
Design; Synthesis; Benzothiazine-3-carboxamide 1,1-dioxide; Integrase; Anti-HIV; INTEGRASE INHIBITORS; METAL-COMPLEXES; ANTIRETROVIRAL THERAPY; BINDING; DOMAIN; RALTEGRAVIR; PIROXICAM; PROGRESS;
D O I
10.22037/ijpr.2020.114153.14695
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A novel series of benzothiazine-3-carboxamide 1,1-dioxide derivatives by modifying the piroxicam scaffold was designed, synthesized, and evaluated as anti-HIV agents. The 1,2-benzothiazine-3-carboxamide 1,1-dioxide scaffold consists of hydroxy and carboxamide groups as a chelating motif to form an interaction with Mg2+ ions within the integrase active site as a target. Most of the compounds displayed encouraging anti-HIV activity in a cell-based assay. Among them, compounds 13d, 13l and 13m were the most potent with EC50 values ranging from 20-25 mu M and SI > 26. Docking study of compounds in integrase active site proposed that the mechanism of action of compounds might be through Mg2+ chelation within integrase active site. The lack of severe cytotoxicity and favorable anti-HIV activity of benzothiazine-3-carboxamide 1,1-dioxide derivatives support further modifications to improve the potency.
引用
收藏
页码:1 / 12
页数:12
相关论文
共 43 条
[1]   Clinical progress of HIV-1 integrase inhibitors [J].
Al-Mawsawi, Laith Q. ;
Al-Safi, Rasha I. ;
Neamati, Nouri .
EXPERT OPINION ON EMERGING DRUGS, 2008, 13 (02) :213-225
[2]  
[Anonymous], HYPERCHEM TM PROFESS
[3]   Highly active antiretroviral therapy: Current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome [J].
Barbaro, G ;
Scozzafava, A ;
Mastrolorenzo, A ;
Supuran, CT .
CURRENT PHARMACEUTICAL DESIGN, 2005, 11 (14) :1805-1843
[4]   Solution structure of the N-terminal zinc binding domain of HIV-1 integrase [J].
Cai, ML ;
Zheng, RL ;
Caffrey, M ;
Craigie, R ;
Clore, GM ;
Gronenborn, AM .
NATURE STRUCTURAL BIOLOGY, 1997, 4 (07) :567-577
[5]   Recent advances in the discovery of small-molecule inhibitors of HIV-1 integrase [J].
Choi, Eungi ;
Mallareddy, Jayapal Reddy ;
Lu, Dai ;
Kolluru, Srikanth .
FUTURE SCIENCE OA, 2018, 4 (09)
[6]   Mononuclear metal complexes with Piroxicam:: Synthesis, structure and biological activity [J].
Christofis, P ;
Katsarou, M ;
Papakyriakou, A ;
Sanakis, Y ;
Katsaros, N ;
Psomas, G .
JOURNAL OF INORGANIC BIOCHEMISTRY, 2005, 99 (11) :2197-2210
[7]   Current status and prospects of HIV treatment [J].
Cihlar, Tomas ;
Fordyce, Marshall .
CURRENT OPINION IN VIROLOGY, 2016, 18 :50-56
[8]   Anti-inflammatory compounds as ligands in metal complexes as revealed in x-ray structural studies [J].
Cini, R .
COMMENTS ON INORGANIC CHEMISTRY, 2000, 22 (3-4) :151-186
[9]   METAL-COMPLEXES OF THE ANTIINFLAMMATORY DRUG PIROXICAM [J].
CINI, R ;
GIORGI, G ;
CINQUANTINI, A ;
ROSSI, C ;
SABAT, M .
INORGANIC CHEMISTRY, 1990, 29 (26) :5197-5200
[10]   Raltegravir: The First HIV Integrase Inhibitor [J].
Cocohoba, Jennifer ;
Dong, Betty J. .
CLINICAL THERAPEUTICS, 2008, 30 (10) :1747-1765